The International Day celebrating girl child has been on the news for the good reasons. Esha Bahal, a simple yet smart student of the Noida University has bagged the prestigious position of British High Commissioner to India for a time of 24 hours.
This comes as a huge feather to the cap of Indian citizens, as Esha achieved the prominent position by subsequently winning a tough competition organized by British High Commission. The commission had held the event to mark the achievement of International Day for Girl Child, which is listed on October 11 every year.
The competition was carried out with a total of 58 women participating. Within this, age group was solely focused in between 18 and 23 across the whole nation. The contest was judged on a short video presentation of the theme of gender equality and its meaning. Esha subsequently put forward the ideas and theories that made her win the competition.
Furthermore, reactions were overwhelming across the nation. Esha, on expressing her opinions further plans to be a social entrepreneur after her higher studies are completed. Currently, she is studying public policy and law which truly describes her vision.
The British High Commissioner even shared the view of the delight of Esha winning the competition, and provide young Indian women a platform to discuss their rights. Several women in India still face the dominance of inequality over gender issues. This can be a turning point for them. With prevailing situations across the country, surrounding women inequality, and discrimination, the news of her winning did annoy and impressed several fighters who gave their best wishes to Esha.
Chilled Pasta market in the United States of America registered a positive compound annual growth rate (CAGR) of 4.85% during the period 2012 to 2017 with a sales value of USD 316.74 Million in 2017, an increase of 4.55% over 2016. The market achieved its strongest performance in 2016 when it grew by 4.97% over its previous year and its weakest performance in 2017 when it increased by 4.55% over 2016.
The market research handbook acts as an essential tool for companies active or planning to venture into the United States of Americas Chilled Pasta (Pasta & Noodles) market. The comprehensive statistics within the research handbook provides insight into the operating environment of the market and also ensures right business decision making based on historical trends and industry model based forecasting
Sales Values in the handbook are depicted in USD ($) and local currency of country and Volumes are represented in M Kilograms.
Overall Chilled Pasta (Pasta & Noodles) market value and volume analytics with growth analysis from 2012 to 2022.
Value and Volume terms for the top brands.
Distribution channel sales analytics from 2014-2017.
Reasons to buy
Get access to authoritative and granular data on the Chilled Pasta (Pasta & Noodles) market and fill in the gaps in understanding of trends and the components of change behind them.
Enhance your understanding of the market to update your strategic and tactical plans based on volume and value changes, brand dynamics and distribution trends.
Analyze the components of change in the market by looking at historic and future growth patterns.
Use the data to understand future patterns of the market trends from winners and losers to category dynamics and thereby quickly and easily identify the key areas in which you want to compete in the future.
TheUnited States Wind power report provides detailed insights into the current power market conditions in the country. Strategic analysis review of the country’s power sector is included, providing recent trends and investment drivers, factors set to shape the future of the industry, and detailed SWOT Analysis
The electricity research work analyzes the power supply scenario in the United States. Installed capacity and generation together with major power plants in
The United States are detailed in the report. In addition to operational plant details, the report also provides planned and under construction power plants in the country.
On the outlook front, installed capacity, power generation (Wind) are forecast to 2025. Further, supporting macroeconomic forecasts including GDP, population are also forecasted.
The report compares the United States power market with its peer markets in terms of supply, infrastructure, demand and growth potential. Further, region and global power market outlook are presented in the report to enable users to assess the United States power market in the global context.
The United States electricity operators including power generation companies, power transmission companies, regulators and regulations, tariffs are provided in the report. Further, company profiles of three leading players in the United States power industry are provided.
Why procure this report?
The unique research work enables users to direct their investments in the right place. Further, procuring the report strengthens user’s decision making and design effective strategies backed up with strong data and analysis back up. Further, it enables quick identification of future trends, regulatory changes and also enables users to identify potential partners while understanding competitor moves and investments.
Data and analysis are presented in a most user-friendly format and is prepared through rigorous primary and secondary research efforts, saving loads of time and efforts for the procuring decision markers and analysts.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications.
What is CAR-T Cell Therapy?
Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
How Does CAR-T Cell Therapy Work?
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.
Like all cancer therapies, CAR-T cell therapy can also cause a number of side effects. However, all these side effects can be managed with standard supportive therapies including steroids. The widespread research activities, worldwide clinical trials and treatments in a limited number of U.S. hospitals have created a robust CAR T-cell market with an estimated CAGR of 6.3% per year. This billion dollar market and projected growth would have been not possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers.
Market for CAR-T Cell Therapy :
CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.
There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.
The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.
Driving Forces for the CAR-T Therapy Market :
With growing demand for CAR-T therapies, CAR-T companies are proliferating. Growing numbers of these companies are supported by:
Increasing investment flowing into CAR-T cell research
Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)
Major acquisitions within the CAR-T industry
Large IPOs within the CAR-T industry
As mentioned, 2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat acute lymphoblastic leukemia. Kite Pharma produced Yescarta, a CAR-T therapy to treat adult patients with certain types of large B-cell lymphoma who did not respond to or who relapsed after other kinds of treatment. In August 2018, both Kymriah and Yescarta secured approval in Europe from the EMA.
Reason to buy :
Get informed about the rapidly evolving CAR-T market
Identify opportunities for CAR-T product development
Reveal the identities of competitors developing CAR-T products and technologies
Access market size data, market segmentation, and 5-year projections through 2024
Determine company strategy or purse funding from investors
Make smarter decisions, faster